A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients

M. Mori, H. Nisimura, A. Urabe, K. Tamura, S. Makino, K. Okabe, J. Tomiyama, M. Hara, M. Tanimoto, M. Kikuchi, H. Hamaguchi, H. Sato, Y. Saburi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twenty-nine patients aged 60-75 years with newly diagnosed acute myelogenous leukemia (AML) were randomized to receive BHAC-DM either at a reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day) or the conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day). On day 7, patients were given therapy for 2 more days if the ratio of blasts in their bone marrow was more than 15%. Granulocyte-colony stimulating factor was injected when the leukocyte count decreased below 1,000/microliter. The rates of complete remission were 46.2% in the S-1 group and 43.8% in the S-2 group. No significant differences in response distinguished the 2 groups. The mortality rate during myelosuppression was 1/13 in the S-1 group and 1/16 in the S-2 group. The rate of treatment-related death was 10.1% for all patients. Grade-4 adverse effects were not seen in any of the patients. We concluded that the conventional dose of BHAC-DM was as acceptable as the reduced dose in elderly patients with AML.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume41
Issue number2
Publication statusPublished - Feb 2000

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients'. Together they form a unique fingerprint.

Cite this